# Trade Mark Journal No.2025/047 21 November 2025

## UK00004291986 10 November 2025 (5,42)

Cristavita

Class 5
  Biopharmaceuticals for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical products for the treatment of viral diseases; Anti-infectives; Chemotherapeutics; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the prevention of ocular diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of autoimmune disorders; Medicines for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of Musculo-skeletal disorders; Pharmaceutical preparations for the treatment of diseases of the metabolic system; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of diseases of the endocrine system; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of kidney diseases; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations for the treatment of diseases of the genitourinary system; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations for the prevention of ocular disorders; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention of diseases of the metabolic system; Medicines for the treatment of cardiovascular and cerebrovascular diseases ; Pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; Pharmaceutical preparations for the prevention of diseases of the endocrine system; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the treatment of tumours; Pharmaceutical preparations for treating skeletal diseases; Pharmaceutical preparations for the prevention of diseases of the genitourinary system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for treating metabolic disorders; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical preparations for the treatment of disorders of the metabolic system; Pharmaceutical preparations for the treatment of kidney disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of disorders of the endocrine system; Pharmaceutical preparations for the prevention of diseases of the respiratory system; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of disorders of the genitourinary system; Pharmaceutical preparations for the prevention of disorders of the metabolic system; Pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; Pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; Topical ophthalmic anti-infective substances for the treatment of infections; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of epilepsy; Pharmaceutical preparations for the prevention of disorders of the endocrine system; Medicinal preparations for the treatment of infectious diseases; Pharmaceutical preparations and substances for the prevention of cancer; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical drugs; Cardiovascular pharmaceuticals; Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the prevention of disorders of the genitourinary system; Antidiabetic pharmaceuticals; Nutraceuticals for therapeutic purposes; Pharmaceutical preparations for the prevention of diseases of the nervous system; Parenteral anti-epileptic pharmaceutical preparations; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the treatment of hyperlipidemia; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for use in hematology; RNA synthesis inhibitors; Pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical products for the treatment of depression; Antitumor drugs; Compounds for treating respiratory diseases; Antiviral prodrugs; Dermatological pharmaceutical products; Pharmaceutical preparations for the treatment of heart rhythm disorders; Immunotherapeutic agents for bacterial infections; Pharmaceutical preparations for the treatment of esophagitis; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for treating skin disorders; Antiviral drugs for treating influenza; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for treating arthritis; Medicines for intestinal disorders; Pharmaceutical preparations for the prevention of disorders of the nervous system; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the treatment of hypercholesteremia.
Class 42
  Development of pharmaceutical preparations and medicines; Consultancy relating to research and development in the field of therapeutics; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research and development services; Research of pharmaceuticals.

Simon Bradley